Beta-transducin repeats-containing proteins (b-TrCP) serve as the substrate recognition subunits for the SCF b-TrCP E3 ubiquitin ligases. These ligases ubiquitinate specifically phosphorylated substrates and play a pivotal role in the regulation of cell division and various signal transduction pathways, which, in turn, are essential for many aspects of tumorigenesis. We review the functions of the SCF b-TrCP ligases in the light of their relevance to cell growth, survival and transformation. Mechanisms underlying b-TrCP regulation and their aberration in human and animal cancer as well as prospective of targeting bTrCP as a means of anticancer therapy are also discussed.
The ubiquitin proteasome pathway controls degradation of the majority of regulatory eukaryotic proteins including those that play a key role in tumorigenesis (Fuchs, 2002) . E3 ubiquitin protein ligases determine substrate specificity and the timing of ubiquitination for given substrates. Posttranslational modifications of ubiquitination substrates such as phosphorylation and hydroxylation may enable recognition of substrates by some of the E3s (Joazeiro and Weissman, 2000; Weissman, 2001) . SCF (Skp1-Cullin1-Fbox protein) E3 ubiquitin ligases recognize specifically phosphorylated substrates and confer their ubiquitination. Modular organization of the SCF complexes permits these E3 ligases to ubiquitinate a wide range of substrates depending on a given F-box protein (Deshaies, 1999) .
F-box proteins serve as the substrate-recognizing subunits, which recruit the core ligase components of SCF via F-box-dependent binding to Skp1 (Bai et al., 1996) . Substrate specificity of F-box proteins is determined by carboxy-terminal protein-protein interaction motifs, including WD40 repeats, leucine-rich repeats and a cohort of poorly characterized or unknown motifs. Correspondingly, F-box proteins are classified as Fbw, Fbl and Fbx (Cenciarelli et al., 1999; Winston et al., 1999a) .
Beta-transducin repeat-containing proteins (b-TrCP, also termed Fbw1) utilize seven WD40 repeats to interact with substrates phosphorylated within the DSG(X) 2 þ n S destruction motifs (Laney and Hochstrasser, 1999; Maniatis, 1999) . SCF b-TrCP E3 ligases mediate ubiquitination and proteasomal degradation of phosphorylated substrates that play a key role in the signal transduction and cell cycle regulation including inhibitors of nuclear factor-kB (IkB), b-catenin and Emi1. In this review, we will focus on the role of b-TrCP in various signaling and cell cycle events that affect cell transformation and survival as well as regulation of b-TrCP activities and their potential aberrations that may be relevant to tumorigenesis.
b-TrCP subfamily of the F-box proteins b-TrCPs (also termed FWD1) belong to a larger family of Fbw (F-box/WD40 repeat containing) proteins whose common features are the presence of a 42-48 amino-acid F-box motif at the N-terminus and seven WD40 repeats at the C-terminus. Members of this subfamily include the Drosophila Slimb protein (Jiang and Struhl, 1998) , Xenopus b-TrCP (Spevak et al., 1993) , as well as mammalian b-TrCP1 (also termed FWD1 or Fbw1a; Margottin et al., 1998; Yaron et al., 1998) and b-TrCP2 (also termed HOS or Fbw1b; Fuchs et al., 1999; Suzuki et al., 1999a; Bhatia et al., 2002) .
b-TrCPs are highly conserved from Xenopus to humans, especially within the functionally important F-box motif and WD40 repeats motif. In addition, a similar organization of genes is reported for Xenopus b-TrCP (Ballarino et al., 2002) and human b-TrCP1 (mapped to chromosome 10q24, Chiaur et al., 2000 , and human b-TrCP2 (localized at chromosome 5q35, Koike et al., 2000) genes. Similar to Xenopus b-TrCP, human b-TrCP1 and b-TrCP2 exist in multiple isoforms due to the expression of alternatively spliced mRNA, all of which encode the proteins containing F-box and all seven WD40 repeats (Yaron et al., 1998; Koike et al., 2000) .
Differences in sequences between mammalian bTrCP1 and b-TrCP2 are most noticeable in their Nterminal parts, which are proximal to the F-box motif. It has been suggested that N-terminal sequences of bTrCP1 and b-TrCP2 allow these proteins to undergo homo-and hetero-dimerization. Although it was further suggested that homodimerization may contribute to the ability of b-TrCP to mediate ubiquitination of IkB (Suzuki et al., 2000) , the functional significance of these interactions and their regulations in cells are yet to be elucidated. A redundant role of mammalian b-TrCP1 and b-TrCP2 in ubiquitination and degradation of Emi1, IkB and b-catenin was proposed on the basis of RNAi analysis and data from mice with genetic ablation of b-TrCP1 (Guardavaccaro et al., 2003; Nakayama et al., 2003) .
Substrate recognition and ubiquitination by SCF b-TrCP
The characteristics of a substrate for SCF b-TrCP E3 ligase include the integrity of the DSG(X) 2 þ n S destruction motif, where serines are phosphorylated by specific kinases, as well as a preference for the presence of lysine residues for ubiquitin conjugation in positions 9-13 upstream from this destruction motif. Understanding of a functional significance of the destruction motif led to the discovery of b-TrCP as a component of a ubiquitin ligase. Earlier reports indicated that a phosphorylationdependent destruction motif (DpSGXXpS) was essential for ubiquitination and degradation of IkB species (Yaron et al., 1997) . Similarity of phosphorylationdependent destruction motifs within IkB and b-catenin was further noted, implicating that ubiquitination of these proteins is mediated by the same E3 ligase (Aberle et al., 1997; Orford et al., 1997) . In Drosophila, deletion of Slimb gene, which encodes an F-box/WD40 repeatscontaining protein, led to accumulation of b-catenin orthologue Armadillo, indicating that mammalian homologues of Slimb may regulate ubiquitination of b-catenin and IkB (Jiang and Struhl, 1998) . Human bTrCP1 was discovered as a protein interacting with HIV-1 Vpu protein, harboring a DSGXXS motif (Margottin et al., 1998) , and the role of b-TrCP in ubiquitination and degradation of b-catenin and IkB was extensively documented (Yaron et al., 1998; Fuchs et al., 1999; Hart et al., 1999; Hatakeyama et al., 1999; Kitagawa et al., 1999; Kroll et al., 1999; Latres et al., 1999; Spencer et al., 1999; Suzuki et al., 1999b; Winston et al., 1999b) .
Mutation analysis of the DSGXXS motif revealed that interaction of IkB with SCF b-TrCP absolutely requires the phosphorylation of both serines within DSGXXS (Alkalay et al., 1995; Yaron et al., 1997) and the presence of an acidic residue at position -1 from the first serine, whereas glycine at þ 1 position was needed for maximal ubiquitination .
Recent advances in solving the structure of SCF complexes provide an insight into the mechanisms underlying the ability of this ligase to recognize and ubiquitinate phosphorylated substrates (Schulman et al., 2000; Zheng et al., 2002; Orlicky et al., 2003) . SCF complexes exhibit a fairly rigid conformation that allows substrate positioning between substrate-recognizing motifs within the F-box protein and E2, which is recruited by the core ligase components. SCF
interacts with a substrate via the binding of aspartic acid and phosphorylated serines within the destruction motif to the opening of a channel within a funnel-like structure shaped by the WD40 domains of b-TrCP1. This binding positions substrates in a way allowing orientation of its ubiquitin-acceptor lysine residues toward recruited E2 .
This model allows recognition of substrates harboring a DSG(X) n S motif where n42 as long as the spatial characteristics of polypeptide chain permit close positioning of phosphorylated serines. In some of the SCF b-TrCP substrates, a linker between Gly and the second serine indeed includes more than two amino acids (Orian et al., 2000; Lassot et al., 2001; Lang et al., 2003) . These data indicate that, in addition to known bTrCP substrates that contain DSGXXS motifs, many additional potential targets of ubiquitination by SCF b-TrCP may exist. Various kinases that are involved in phosphorylating serines within these destruction motifs are expected to contribute to the regulation of stability of these substrates (Table 1) .
Role of b-TrCP in NF-jB signaling pathway

Degradation of IkB
NF-kB is an inducible transcription factor, which is involved in inflammation, stress, immune response and malignant transformation. In nonstimulated cells, NFkB is retained in a latent form in the cytoplasm by a family of inhibitory molecules (IkBs), which are capable of binding the SCF b-TrCP ubiquitin ligase upon phosphorylation by an inducible IkB kinase complex (IKK). Phosophorylated IkB undergoes ubiquitination and 26S proteasome-dependent degradation (reviewed in Karin and Ben-Neriah, 2000) , thereby relieving NF-kB from its inhibition and enabling NF-kB to translocate to the nucleus. In the nucleus, NF-kB activates transcription of a large number of target genes, including those involved in cell growth and inhibition of apoptosis and, thus, play a pivotal role in tumor development and progression (reviewed in Mayo and Baldwin, 2000; Bharti and Aggarwal, 2002) .
Enhanced constitutive activity of NF-kB has been widely observed in several human tumor cells and primary tumors, including prostate, colon, lung and breast cancers, multiple myeloma, pancreatic carcinoma and neuroblastoma (reviewed in Joyce et al., 2001; Karin et al., 2002) . Whereas aberrant activation of NF-kB in tumor cells often occurs due to the oncogenic activation of IKK activities (Mayo and Baldwin, 2000; Joyce et al., 2001; Richmond, 2002) , an increase in SCF b-TrCP E3 ligase activity in tumor cells may also contribute to this phenomenon (this review, Figure 1 ).
Processing/degradation of NF-kB precursors
NF-kB activity is also regulated at the level of processing of the NF-kB1 and NF-kB2 precursor proteins p105 and p100 to their respective p50 and p52 subunits, which participate in the formation of NF-kB dimeric transcription factor (Siebenlist et al., 1994; Baldwin, 1996) . Both p105 and p100 contain ankyrin repeats within their C-terminal domains and function as IkB-like inhibitors (Rice et al., 1992; Mercurio et al., 1993) . Phosphorylated p105 and p100 undergo ubiquitination in a manner dependent on SCF b-TrCP (Heissmeyer et al., 1999 (Heissmeyer et al., , 2001 ). This ubiquitination leads to either degradation of p105 and p100 and liberation of sequestered NF-kB dimers or the processing of these precursors into mature p50 and p52 subunits (Orian et al., 2000; Fong and Sun, 2002; Lang et al., 2003) . Whereas it is not clear how b-TrCP-mediated ubiquitination differentiates between complete and partial degradation of NF-kB precursors, it is reasonable to point out that both of these b-TrCP-dependent events contribute to NF-kB induction, and hence deregulated activation of these mechanisms may contribute to human malignancies. Indeed, truncating mutations, which constitutively produce p52 subunit, are found in B and T cell lymphomas (Karin et al., 2002) .
Role of b-TrCP in b-catenin/Tcf pathway
The b-catenin/Tcf signal transduction pathway is implicated in malignant transformation of many types of human cells. Protein stability of b-catenin is pivotal for this signaling, and b-catenin is frequently stabilized in colorectal cancer, hepatocellular carcinomas and malignant melanomas. Stabilization of b-catenin leads to its accumulation, translocation into the nucleus and binding to Tcf/Lef transcription factors, followed by the induction of transcription of a number of oncogenes including c-myc and cyclin D1 (Polakis, 1999 (Polakis, , 2000 . SCF b-TrCP ubiquitinates b-catenin, which is phosphorylated within the destruction motif under normal growth conditions Hart et al., 1999 Winston et al., 1999b) . This phosphorylation relies on tethering b-catenin to a multisubunit complex, which is comprised of glycogen synthase kinase (GSK3b), casein kinase I (CKI), tumor suppressor adenomatous poliposis coli (APC) protein and axin (Polakis, 1999 (Polakis, , 2000 Gao et al., 2002; Liu et al., 2002) . In this complex, CKI elicits 'priming' phosphorylation of b-catenin at Thr41 and Ser45 (Gao et al., 2002; Liu et al., 2002) , thus allowing consequent phosphorylation of b-catenin by GSK3b at Ser33 and Ser37 within the destruction motif. Abrogation of N-terminal phosphorylation of b-catenin leads to its stabilization and accumulation (Maniatis, 1999; Polakis, 1999 Polakis, , 2000 . This abrogation may result from the tumor-associated mutations in the b-catenin phosphoacceptor sites (including sites for both CKI and GSK3b), or from the failure to recruit GSK3b due to the inactivating mutations in APC or axin, or from the inhibition of GSK3b activity by induction of upstream pathways by ligands, such as Wnt and/or growth factors (Polakis, 1999 (Polakis, , 2000 . Phosphorylation-independent ubiquitination and degradation of b-catenin via the Ebi F-box protein and Siah1 E3 ligase was recently reported (Liu et al., 2001; Matsuzawa and Reed, 2001) , although its role in preventing stabilization of b-catenin in tumors remains to be clarified. Whereas an inhibition of b-TrCP function promotes b-catenin stabilization in experimental conditions, it remains to be seen whether tumor cells utilize this mechanism in vivo along with the aberrations of b-catenin phosphorylation (this review).
Role of b-TrCP in regulation of cell cycle
Earlier observations demonstrating that cells from Drosophila Slimb mutants exhibit additional centrosomes and mitotic defects indicated that b-TrCP may be involved in regulating cell division (Wojcik et al., 2000) . Defects in male fertility concurrent with an accumulation of metaphase I spermatocytes in testes were observed in b-TrCP1 knockout mice. Furthermore, embryo fibroblasts from these mice exhibited centrosome overduplication and impaired progression through mitosis (Guardavaccaro et al., 2003; Nakayama et al., 2003) . These defects are attributed to stabilization of an inhibitor of the anaphase-promoting complex, Emi1, which is ubiquitinated by SCF b-TrCP in a manner dependent on phosphorylation by Cdc2 that occurs in S and G2 phases of cell cycle (Guardavaccaro et al., 2003; Margottin-Goguet et al., 2003) .
In addition, the potential contribution of b-TrCP in controlling the activities of other regulators of cell cycle cannot be ruled out. For example, SCF b-TrCP controls the extent of NF-kB and b-catenin/Tcf signaling. Intriguingly, both of these pathways are converged in regulating activity of cyclin D1 gene promoter (Albanese et al., 2003) . In addition, a recent report implicates b-TrCP in ubiquitination and degradation of human discs large (hDlg) tumor suppressor protein, which contributes to the maintenance of cell-cell contact and is involved in the regulation of cell adhesion and proliferation. Intriguingly, in epithelial cells, hDlg degradation and downregulation is implicated in loss of the differentiation and in neoplastic transformation, as well as subsequent progression of tumors derived from these cells towards a metastatic phenotype (Mantovani and Banks, 2003) . Future evaluation of b-TrCP activities in these tumors and their metastases will be of significant interest.
Regulation of b-TrCP activities
Endogenous b-TrCPs are expressed at low levels and their function can be easily disrupted by the expression of either dominant-negative constructs (Deshaies, 1999; Maniatis, 1999) , or short inhibitory RNA (Guardavaccaro et al., 2003) or pseudosubstrates . Conversely, forced expression of b-TrCP often results in accelerated degradation of their substrates Hart et al., 1999; Kroll et al., 1999) . These data suggest that effectors controlling the abundance of bTrCP play an important role in the regulation of activities of SCF b-TrCP E3 ligases (Figure 1 ). These activities are regulated by cellular mechanisms that affect localization and abundance of b-TrCP in cells. In addition, an increase in the levels of one phosphorylated substrate may potentially compete for the availability of b-TrCP to interact with another substrate. This mechanism may also be employed by viral pseudosubstrates of SCF b-TrCP such as viral proteins Vpu Besnard-Guerin et al., 2003) and LMP1 .
When human b-TrCPs are transiently expressed in cells, b-TrCP1 predominantly localizes in the nucleus, whereas b-TrCP2 is primarily found in the cytoplasmic compartment (Lassot et al., 2001; Davis et al., 2002) . These immunocytochemical data may suggest that bTrCP1 is mainly responsible for ubiquitination of nuclear substrates, including ATF4 and Emi1. Indeed, Emi1 is accumulated in mitotic embryonic fibroblasts from b-TrCP1 knockout mice, which show minor aberrations in the degradation of IkB (Guardavaccaro et al., 2003; Nakayama et al., 2003) . Nevertheless, these data should not be overinterpreted until the development of a suitable antibody for the analysis of endogenous b-TrCP1 localization. Conversely, whereas endogenous murine b-TrCP2 is predominantly found in the cytoplasm of the cells of mouse tissues (Bhatia et al., 2002) , a putative role for b-TrCP2 in degradation of cytoplasmic proteins must be corroborated by studies in b-TrCP2 knockout animals. In addition, substrate specificity of b-TrCP may be a subject of tissue-and stimuli-specific regulation of their expression (see below).
Nuclear-cytoplasmic shuttling mechanisms regulate localization of b-TrCP1 depending on interaction between b-TrCP1 and its pseudosubstrate hnRNP-U. This interaction is suggested to permit cytoplasmic localization of some of the b-TrCP1 molecules and is thought to enable b-TrCP1 to contribute to the ubiquitination of cytoplasmic substrates. In addition, the association of hnRNP-U stabilizes b-TrCP1. This regulation seems to be specific for b-TrCP1, as b-TrCP2 does not bind to hnRNP-U (Davis et al., 2002) .
Mechanisms regulating the localization of b-TrCP2 remain to be elucidated. b-TrCP2 is an unstable protein, whose proteolysis depends on proteasome pathway . The stability of b-TrCP2 is increased under conditions that lead to activation of IKK, implicating that an increase in the levels of phosphorylated substrate (IkB) may protect b-TrCP2 from degradation (our unpublished data).
Activation of the stress-activated protein kinase pathway increases mRNA levels of b-TrCP1, but not of b-TrCP2, in a transcription-independent manner. This increase leads to a concurrent elevation in the levels of b-TrCP1 and, along with the activation of IKK, contributes to the activation of NF-kB pathway in response to stress (Spiegelman et al., 2001) . In a similar manner, the levels of b-TrCP1 mRNA are robustly increased by activation of Wnt pathway (Spiegelman et al., 2000) , and this increase is likely mediated by mRNA stabilization (our unpublished data). In some types of mammalian cells, induction of b-TrCP1 expression by the b-catenin/Tcf pathway results in an accelerated degradation of properly phosphorylated b-catenin, thus controlling the activities of the b-catenin/Tcf pathway via the negative feedback loop mechanism. However, this mechanism is out of order in tumors cells, in which b-catenin is insensitive to b-TrCP-dependent ubiquitination because of lack of specific phosphorylation (e.g. due to mutations in APC or b-catenin).
Indeed, accumulation of b-catenin is concomitant with high levels of b-TrCP1 in some of the human colorectal tumors. In addition, accumulation of b-TrCP increases NF-kB transactivation, implicating that stabilization of b-catenin caused by sustained activation of Wnt or oncogenic mutations in b-catenin or APC may contribute to NF-kB-dependent survival of tumor cells (Spiegelman et al., 2000) .
Intriguingly, human colorectal tumors, in which the levels of b-TrCP1 are increased, exhibit low levels of bTrCP2 expression. In mouse and human fibroblasts, in which b-TrCP1 is expressed at low levels, activation of Wnt/b-catenin pathway decreases b-TrCP2 expression and NF-kB activation by inhibiting the transcription of b-TrCP2 gene (Spiegelman et al., 2002b) . Conversely, mitogenic stimuli activate b-TrCP2 transcription and increase the levels of b-TrCP2 in a manner dependent on mitogen-activated protein kinase signaling pathway. This activation has been suggested to play an important role in NF-kB-dependent inhibition of cell differentiation and promotion of cell transformation in vitro (Spiegelman et al., 2002a) . In addition to the mechanisms regulating the abundance and localization of b-TrCP, a potential role of post-translational modifications of b-TrCP in the assembly and activity of the SCF b-TrCP E3 ubiquitin ligases will be unveiled by future studies.
As b-TrCPs tend to ubiquitinate multiple substrates, there is a possibility that different substrates may compete for a limited pool of b-TrCP molecules. Evidence for this mechanism comes from a recent report showing that overexpression of ATF4 results in stabilization of b-catenin (Besnard-Guerin et al., 2003) . It is also possible that substrates whose specific phosphorylation within the destruction motif is inducible (such as IkB, p105 or Emi1) would get an upper hand over constitutively phosphorylated substrates (e.g. b-catenin). Although activation of IKKa was shown to lead to accumulation of b-catenin, but not its phosphorylation-deficient mutant (Lamberti et al., 2001) , a putative contribution of a competition for available b-TrCP in this phenomenon remains to be elucidated.
On the other hand, viral proteins that interact with bTrCP may be expressed in cells at very high levels and may decrease the availability of b-TrCP for cellular substrates. HIV-1 Vpu protein, which is a pseudosubstrate for SCF b-TrCP (Margottin et al., 1998) , was shown to inhibit competitively b-TrCP-dependent IkB degradation and NF-kB activation ). This effect of Vpu is implicated in the induction of apoptosis in HIV-infected T cells via inhibition of NFkB-dependent expression of antiapoptotic genes . Furthermore, Vpu expression retains b-TrCP1 in the cytoplasm and leads to stabilization and accumulation of b-catenin (Besnard-Guerin et al., 2003) . In a similar manner, squelching of b-TrCP and restriction of NF-kB induction by another pseudosubstrate, the Epstein-Barr virus LMP1, may affect the transforming activities of LMP1 .
Aberrations of b-TrCP in tumorigenesis
Previous studies provided compelling evidence that NFkB plays an important role in oncogenesis and promotes cell resistance to anticancer therapy (Mayo and Baldwin, 2000; Joyce et al., 2001; Karin et al., 2002) . As b-TrCP proteins are pivotal to the activation of the NFkB pathway, upregulation of NF-kB transactivation via an increase in b-TrCP levels and SCFb -TrCP activities may contribute to malignant transformation of cells (in addition to activation of IKK (Karin et al., 2002; Richmond, 2002 and this review, Figure 1 ). Under these conditions, an elevated expression of b-TrCP is expected to promote cell transformation via activation of NF-kBdependent survival pathways.
Indeed, the current literature indicates that an aberrant upregulation of b-TrCP is often found in cancer cell lines and primary tumors. b-TrCP1 expression and b-TrCP-dependent activation of NF-kB are upregulated by b-catenin/Tcf signaling (see above). In line with this observation, several cases of colorectal cancers with upregulated b-catenin/Tcf signaling exhibit elevated levels of b-TrCP1 protein (Spiegelman et al., 2000) . Overexpression of b-TrCP2 is detected in most of the cell lines derived from human breast and prostate tumors as compared to the nontransformed cell lines of similar tissue origin. Moreover, elevated levels of b-TrCP2 are also observed in a number of tumor tissue samples from the patients with primary prostate, breast and gastric cancers (Saitoh and Katoh, 2001; Spiegelman et al., 2002a) . In addition, b-TrCP2 is overexpressed in chemically induced mouse skin tumors, and its overexpression (but not elevated IkB phosphorylation) coincides with the accelerated degradation of IkB in vivo, and constitutive activation of NF-kB signaling in mouse skin tumors (Budunova et al., 1999; Bhatia et al., 2002) . These data indicate that overexpression of b-TrCP1/b-TrCP2 may represent a common trend in a variety of human and mouse tumors. This overexpression and activation of b-TrCP function may play a significant role in tumorigenesis via activation of NF-kB-dependent antiapoptotic pathways.
b-TrCP also regulates the stability of b-catenin and, hypothetically, mutations in b-TrCP might cause stabilization of b-catenin in tumors. However, this possibility seems counterintuitive in light of the importance of b-TrCP function in NF-kB signaling, together with the fact that tumors often harbor mutations in either APC or b-catenin, which abrogate phosphorylation of b-catenin and render it insensitive to b-TrCP-mediated degradation. In addition, activation of mitogen signaling, which is a hallmark of many tumors (Mayo and Baldwin, 2000; Joyce et al., 2001) , may inhibit GSK3b (Eldar-Finkelman et al., 1995) and, thus, phosphorylation of b-catenin in the absence of mutations. Indeed, human colorectal tumors and mouse skin tumors are characterized by a high level of nucleocytoplasmic b-catenin and constitutively active b-catenin/Tcf signaling, despite the overexpression of b-TrCP (Spiegelman et al., 2000; Bhatia et al., 2002 ; our unpublished data).
Moreover, mutations in b-TrCP are rarely, if ever, found in human tumors, including colorectal cancers, which are wild type for b-catenin and APC (Winston et al., 1999b) . No major chromosomal alterations in bTrCP1 were detected in 90 samples from human tumor cell lines and primary cancers (Chiaur et al., 2000) . Neither were mutations of b-TrCP1 found in 37 primary malignant melanomas (Reifenberger et al., 2002) .
The vast majority of analysed samples from human prostate and gastric cancers revealed no mutations in the b-TrCP1/b-TrCP2 genes (Saitoh and Katoh, 2001; Gerstein et al., 2002) . However, the expression of deletion mutants of b-TrCP1 transcript was detected in one prostate cancer cell line (TSU), and one prostate cancer xenograft (Gerstein et al., 2002) . The first is a 96-bp deletion that generates stop codon at position 212, leading to the expression of truncated b-TrCP1 that lacks substrate-recognizing WD40 repeats. The second is a 169-bp deletion leading to in-frame deletion from residues 17 to 73 (Gerstein et al., 2002) . Although one may speculate that these mutations impair b-catenin ubiquitination and degradation, and could be a cause of observed b-catenin activation in these cells, other evidence does not favor this hypothesis. For example, the TSU prostate cancer cell line exhibits high levels of b-TrCP2 expression (Spiegelman et al., 2002a) and constitutively activated NF-kB signaling (Suh et al., 2002) , which implies the presence of fully functional SCF b-TrCP E3 ubiquitin ligase in these cells. In addition, the heterozygous nature of these mutations (Gerstein et al., 2002) raises further questions as per their role in the stabilization and activation of b-catenin in TSU cells.
A point mutation leading to F462S amino acid substitution within the seventh WD40 repeat domain of b-TrCP2 was identified in one gastric cancer cell line (OKAJIMA) (Saitoh and Katoh, 2001 ). However, a potential role for this mutation in the alteration of b-catenin recognition by b-TrCP2 requires further studies. In addition, OKAJIMA cells were demonstrated to overexpress Wnt1 (Katoh, 2003) , which may also cause activation of b-catenin/Tcf signaling in these cells. These data collectively indicate that, despite the role of b-TrCP in b-catenin turnover, it is unlikely that they might function as tumor suppressors.
b-TrCP as potential means and targets for anticancer therapy
Given that NF-kB activities are important for survival of cancer cells, inhibition of IkB degradation via blocking b-TrCP activities may represent a potentially effective means for cancer treatment. Forced expression of the dominant-negative b-TrCP2 construct inhibits IkB degradation and leads to sensitization of human melanoma cells to apoptosis, induced by various agents including cisplatin and ionizing radiation (Soldatenkov et al., 1999) . In addition, pyrrolidine dithiocarbamate (PDTC), recently rediscovered as an inhibitor of SCF b-TrCP E3 ligase activity (Hayakawa et al., 2003) , is shown to induce apoptosis in mammary adenocarcinoma, neuroblastoma, prostate cancer and colorectal cancer cells (Chinery et al., 1997; Bach et al., 2000; Smirnov et al., 2001; Bian et al., 2002; Gunawardena et al., 2002) , and to inhibit N-nitrosodiethylamineinduced liver carcinogenesis (Hadjiolov et al., 1992) . PDTC is also shown to enhance the efficacy of cytotoxic drugs in the treatment of leukemia and human colorectal cancer cells both in vitro and in vivo (Osswald and Frank, 1990; Chinery et al., 1997; Bach et al., 2000) . These data provide evidence that endogenous SCF b-TRCP ubiquitin ligase activities represent a promising target for adjuvant therapy of human cancers, as well as a target for chemoprevention. Another possible utilization of b-TrCP in anticancer therapy is deployment of the SCF b-TRCP ubiquitin ligase machinery to target the degradation of specific diseasecausing proteins, which are not natural b-TrCP substrates. Two approaches have been successfully used to direct the degradation of otherwise stable cellular proteins. One of the strategies is to utilize SCF ubiquitin-conjugating machinery when b-TrCP is fused with specific motifs (e.g. human papillomavirus E7), which recognize target proteins (e.g., retinoblastoma) (Zhou et al., 2000) . A recent report provides evidence that this design is also successful in targeting degradation of a stable b-catenin mutant (Cong et al., 2003) . Another approach includes the synthesis of proteolysistargeting chimeric molecules (Protacs) to link a b-TrCPrecognized destruction motif derived from IkB with a small ligand molecule, which is recognized by a targeted receptor. In this case, endogenous SCF b-TrCP is directed to ubiquitinate this receptor (Sakamoto et al., 2001) . Both methodologies were shown to be effective in targeting foreign substrates for ubiquitination by SCF b-TrCP and subsequent degradation. These approaches could potentially be utilized in gene therapy of tumors when targeted against transforming oncogenes.
